Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

C-3 Amido-indole cannabinoid receptor modulators.

John Hynes1, Katerina Leftheris, Hong Wu

  • 1Discovery Chemistry, Bristol-Myers Squibb, Princeton, NJ 08543-4000, USA. john.hynes@bms.com

Bioorganic & Medicinal Chemistry Letters
|August 6, 2002
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structure-Based Design of Novel TLR7/8 Agonist Payloads Enabling an Immunomodulatory Conjugate Approach.

ACS medicinal chemistry letters·2025
Same author

Repression of Organic Anion Transporting Polypeptide (OATP) 1B Expression and Increase of Plasma Coproporphyrin Level as Evidence for OATP1B Downregulation in Cynomolgus Monkeys Treated with Chenodeoxycholic Acid.

Drug metabolism and disposition: the biological fate of chemicals·2022
Same author

Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1<i>H</i>-pyrazol-1-yl)methyl)phosphonate (BMS-820132).

Journal of medicinal chemistry·2022
Same author

Azatricyclic Inverse Agonists of RORγt That Demonstrate Efficacy in Models of Rheumatoid Arthritis and Psoriasis.

ACS medicinal chemistry letters·2021
Same author

Tricyclic-Carbocyclic RORγt Inverse Agonists-Discovery of BMS-986313.

Journal of medicinal chemistry·2021
Same author

Quantification of surrogate monoclonal antibodies in mouse serum using LC-MS/MS.

Bioanalysis·2021

New C-3 amido-indole compounds selectively target the CB2 receptor. These optimized compounds show potent in vivo activity in reducing inflammatory cytokine production, specifically TNF-alpha release.

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Immunology

Background:

  • The endocannabinoid system, particularly the CB2 receptor, is a key target for modulating inflammatory responses.
  • Tumor Necrosis Factor-alpha (TNF-alpha) is a pro-inflammatory cytokine implicated in various disease states.

Purpose of the Study:

  • To discover and optimize novel C-3 amido-indole derivatives with selective binding affinity for the CB2 receptor.
  • To evaluate the in vivo efficacy of these compounds in suppressing lipopolysaccharide (LPS)-induced TNF-alpha release in a murine model.

Main Methods:

  • Synthesis and structure-activity relationship (SAR) studies of C-3 amido-indole analogs.
  • In vitro receptor binding assays to determine CB2 selectivity.
  • In vivo assessment of anti-inflammatory activity using LPS-challenged mice to measure TNF-alpha levels.

Related Experiment Videos

Main Results:

  • Several C-3 amido-indole compounds demonstrated selective binding to the CB2 receptor over the CB1 receptor.
  • Optimized compounds exhibited significant in vivo potency in reducing LPS-induced TNF-alpha release in murine models.
  • The SAR studies successfully guided the optimization process towards highly active compounds.

Conclusions:

  • C-3 amido-indole derivatives represent a promising class of selective CB2 receptor modulators.
  • These compounds hold potential as therapeutic agents for inflammatory conditions characterized by elevated TNF-alpha levels.